First Time Loading...

JW (Cayman) Therapeutics Co Ltd
HKEX:2126

Watchlist Manager
JW (Cayman) Therapeutics Co Ltd Logo
JW (Cayman) Therapeutics Co Ltd
HKEX:2126
Watchlist
Price: 1.7 HKD -2.86% Market Closed
Updated: Apr 27, 2024

JW (Cayman) Therapeutics Co Ltd
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

JW (Cayman) Therapeutics Co Ltd
Revenue Peer Comparison

Comparables:
6160
1801
603392
300122
300896

Competitive Revenue Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
JW (Cayman) Therapeutics Co Ltd
HKEX:2126
Revenue
¥173.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Revenue
¥9.6B
CAGR 3-Years
48%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Revenue
¥6.2B
CAGR 3-Years
17%
CAGR 5-Years
266%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Revenue
¥5.5B
CAGR 3-Years
33%
CAGR 5-Years
41%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Revenue
¥49.7B
CAGR 3-Years
53%
CAGR 5-Years
65%
CAGR 10-Years
50%
Imeik Technology Development Co Ltd
SZSE:300896
Revenue
¥1.9B
CAGR 3-Years
51%
CAGR 5-Years
54%
CAGR 10-Years
N/A

See Also

What is JW (Cayman) Therapeutics Co Ltd's Revenue?
Revenue
173.9m CNY

Based on the financial report for Dec 31, 2023, JW (Cayman) Therapeutics Co Ltd's Revenue amounts to 173.9m CNY.

What is JW (Cayman) Therapeutics Co Ltd's Revenue growth rate?
Revenue CAGR 1Y
19%

Over the last year, the Revenue growth was 19%.